Voyager Therapeutics (VYGR) Financials

$3.02

$-0.08 (-2.43%)

As on 16-Sep-2026 12:36EDT

Market cap

$197 Mln

Revenue (TTM)

$34 Mln

P/E Ratio

--

P/B Ratio

1.3

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	34.46	40.37	80.00	250.01	40.91	37.42
Cost of Revenue	70.35	132.27	4.73	92.17	6.19	73.79
Gross Profit	-35.89	-91.90	80.00	157.84	40.91	37.42
Operating Expenses	81.30	39.94	163.29	35.82	91.74	111.03
Operating Profit (EBIT)	-117.19	-131.84	-83.29	122.01	-50.84	-73.62
Other Income	--	--	--	--	2.65	2.81
Profit before Tax	-107.60	-119.58	-64.34	133.74	-46.39	-71.20
Provision for Tax	0.13	0.14	0.67	1.41	0.02	-5.17
Profit after Tax (Net Income)	-107.73	-119.72	-65.00	132.33	-46.41	-66.03
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-46.41	-71.20

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	154.38	196.08	299.76	236.32	59.02	95.06
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	26.69	29.66	43.50	50.45	27.75	47.82
Current Liabilities	16.69	26.54	49.79	64.51	72.59	50.98
Total Liabilities	214.44	252.28	393.05	351.28	159.36	193.86

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	72.53	49.59	116.24	31.60	34.86	57.16
Current Assets	125.23	202.69	276.81	319.68	124.50	136.70
Total Assets	214.44	252.28	393.05	351.28	159.36	193.86
Total Debt*	32.57	36.50	43.73	20.29	23.13	44.18
Net Current Assets	108.54	176.15	227.02	255.18	51.91	85.72

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-132.47	-15.31	77.92	-12.51	-53.53
Cash Flow from Investing Activities	--	125.45	-94.86	-141.64	-7.34	65.91
Cash from Financing Activities	--	0.82	114.02	33.65	1.11	0.61
Net Cash Inflow / Outflow	--	--	--	--	-18.74	12.99

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-1.82	-2.04	-1.12	2.94	-1.20	-1.75
Cash EPS ($)	--	-1.97	-1.04	3.03	-1.04	-1.61
Adjusted Book Value ($)	--	3.34	5.17	5.24	1.53	2.51
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-2.26	-0.26	1.73	-0.32	-1.42
Free Cash Flow per Share ($)	--	-2.30	-0.32	1.66	-0.39	-1.46

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-41.57	-21.66	78.13	-41.93	-38.71
ROE (%)	-61.48	-48.29	-24.25	89.61	-60.24	-52.96
ROA (%)	-37.24	-37.10	-17.47	51.83	-26.28	-29.00
EBIT Margin (%)	-312.26	-296.17	-80.42	53.49	-124.27	-196.76
Net Margin (%)	-312.63	-296.53	-81.25	52.93	-106.54	-164.15
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-19.07	-0.50	-0.68	5.11	0.09	-0.78
EBIT Growth (%)	-0.32	-85.86	-148.11	363.07	30.94	-368.84
Net Profit Growth (%)	0.19	-84.18	-149.12	385.14	29.72	-279.72
EPS Growth (%)	1.97	-0.82	-1.38	3.44	0.31	-2.78
Book Value Growth (%)	-38.68	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-1.93	-5.06	2.88	-5.07	-1.55
Price / Book Value	1.28	1.18	1.10	1.61	3.98	1.08
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	2.59	-0.61	-1.77	1.23	-3.12	-0.21
Close Price ($)	3.50	3.93	5.67	8.44	6.10	2.71
High Price ($)	5.55	6.27	11.72	14.34	10.60	9.15
Low Price ($)	2.88	2.65	5.19	5.61	2.60	2.46
Market Cap ($ Cr)	196.56	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.19	0.15	0.09	0.39	0.46
Short term debt to equity ratio	0.04	0.04	0.02	0.01	0.05	0.06
Current Ratio	7.51	7.64	5.56	4.96	1.72	2.68
Quick Ratio	7.51	--	--	4.96	1.70	2.65
Interest Coverage	--	--	--	--	-28.37	-188.76

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	9.15	4.36	5.61	33.78	1.56	2.00
Asset Turnover	0.12	0.13	0.21	0.98	0.23	0.16
Receivable days	--	28.28	203.04	62.16	6.19	42.76
Inventory Days	--	--	0.00	1.54	73.42	21.43
Payable days	--	12.44	216.17	8.26	92.63	2.99
Cash Conversion Cycle	--	--	-13.13	55.44	-13.01	61.20

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.